CDH2 and cancer: During cancer progression or under apoptotic stimuli (including therapeutic) conditions, epithelial tumor cells undergo EMT that deeply alters tumor cell features (such as changes in cell polarity and intercellular junctions) and increases the expression of mesenchymal markers (such as N-cadherin and vimentin) [42, 43].